Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
C. Prelli Bozzo, A. Laliberte, A. De Luna, C. Pastorio, K. Regensburger, S. Krebs, A. Graf, H. Blum, M. Volcic, K. M. Sparrer, F. Kirchhoff
This study uses HIV-guided CRISPR to identify antiviral factors by analyzing sgRNA enrichment during viral replication.
bioRxiv · Nov 3, 2023 · PreprintMicrobiology
R. Nchioua, A. Schundner, D. Kmiec, C. Prelli Bozzo, F. Zech, L. Koepke, A. Graf, S. Krebs, H. Blum, M. Frick, K. M. Sparrer, F. Kirchhoff
This study shows that SARS-CoV-2 variants of concern (VOCs) require IFITM2 for efficient replication in human lung cells, with IFITM2 depletion reducing viral RNA and infectious virus production by over four orders of magnitude.
bioRxiv · Nov 17, 2021 · PreprintMicrobiology
M. Hayn, A. Bloetz, A. Rodriguez-Alfonso, S. Vidal, N. Preising, L. Staendker, S. Wiese, C. M. Stuerzel, M. Harms, R. Gross, C. Jung, M. Kiene, B. H. Hahn, T. Jacob, S. Poehlmann, , F. Kirchhoff
The paper identifies a Cystatin C fragment that inhibits GPR15-mediated HIV and SIV infection without affecting GPR15L signaling.
bioRxiv · Oct 26, 2020Microbiology
D. Schuetz, S. Rode, C. Read, J. Mueller, B. Glocker, K. M. Sparrer, O. Fackler, P. Walther, J. Muench
This study shows that peptide nanofibrils enhance viral infection by being actively engaged by cellular protrusions, not through random binding.
bioRxiv · Oct 1, 2020 · PreprintCell Biology
C. Conzelmann, A. Gilg, R. Gross, D. Schuetz, N. Preising, L. Staendker, B. Jahrsdoerfer, H. Schrezenmeier, K. M. Sparrer, T. Stamminger, S. Stenger, J. Muench, J. A. Mueller
This paper introduces an enzyme-based immunodetection assay to quantify SARS-CoV-2 infection by measuring viral spike protein expression in cell cultures.
Antiviral Research · Sep 1, 2020Peer-reviewedMicrobiology
R. Nchioua, D. Kmiec, J. Mueller, C. Conzelmann, R. Gross, C. M. Swanson, S. Neil, S. Stenger, D. Sauter, J. Muench, K. M. Sparrer, F. Kirchhoff
This paper identifies ZAP as an IFN-induced antiviral effector that restricts SARS-CoV-2 by targeting CpG dinucleotides, though SARS-CoV-2 may be adapted to low CpG environments.
bioRxiv · Jun 4, 2020Microbiology